文献速递术前评估与围术期医学

择期手术前青霉素过敏去标签:可行性与障碍

Penicillin allergy de-labelling ahead of elective surgery: feasibility and barriers.
PubMed 文献 · Br J Anaesth · 2018-10-19

本研究在手术预评估门诊对携带未经证实青霉素过敏标签的患者进行风险分层,低风险者接受直接口服阿莫西林递增挑战至总剂量500 mg。219例筛查中74例符合条件,56例接受测试,55例成功去标签,无严重反应;随访中19例里17例手术时接受了适当抗菌预防。仅3/33例去标签患者愿在无专科测试下移除标签。

要点

  • 风险分层后直接口服阿莫西林挑战可用于择期手术前青霉素过敏去标签。
  • 56例测试者中55例去标签,无严重挑战反应或后续严重反应。
  • 患者对测试接受度高,但仅少数愿仅凭病史移除过敏标签。

核心结论

  • 在适当风险分层的患者中,快速直接口服挑战去标签可融入现有手术护理路径,为患者带来即时和潜在长期获益。

研究设计与样本

  • 来自手术预评估门诊的‘青霉素过敏’患者,使用筛查问卷进行风险分层;低风险者接受递增阿莫西林直接口服挑战至总剂量500 mg,并完成3天居家疗程。

主要发现

  • 219例筛查中74例符合条件并获测试邀请,最终56例接受测试,55例去标签。
  • 监督挑战期间及之后无严重反应。
  • 随访中19例去标签患者里17例手术时接受了适当抗菌预防。
  • 33例去标签患者中仅3例愿在无先前专科测试下移除标签。

临床怎么用

  • 对手术预评估中携带青霉素过敏标签者,可用筛查问卷识别低风险患者并提供直接口服挑战去标签。
  • 去标签后应随访手术中抗菌药物使用,以评估临床获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Around 10-15% of the in-patient population carry unsubstantiated 'penicillin allergy' labels, the majority incorrect when tested. These labels are associated with harm from use of broad-spectrum non-penicillin antibiotics. Current testing guidelines incorporate both skin and challenge tests; this is prohibitively expensive and time-consuming to deliver on a large scale. We aimed to establish the feasibility of a rapid access de-labelling pathway for surgical patients, using direct oral challenge. METHODS: 'Penicillin allergic' patients, recruited from a surgical pre-assessment clinic, were risk-stratified using a screening questionnaire. Patients at low risk of true, immunoglobulin E (IgE)-mediated allergy were offered direct oral challenge using incremental amoxicillin to a total dose of 500 mg. A 3-day course was completed at home. De-labelled patients were followed up to determine antibiotic use in surgery, and attitudes towards de-labelling were explored. RESULTS: Of 219 patients screened, 74 were eligible for inclusion and offered testing. We subsequently tested 56 patients; 55 were de-labelled. None had a serious reaction to the supervised challenge, or thereafter. On follow-up, 17 of 19 patients received appropriate antimicrobial prophylaxis during surgery. Only three of 33 de-labelled patients would have been happy for the label to be removed without prior specialist testing. CONCLUSION: Rapid access de-labelling, using direct oral challenge in appropriately risk-stratified patients, can be incorporated into the existing surgical care pathway. This provides immediate and potential long-term benefit for patients. Interest in testing is high among patients, and clinicians appear to follow clinic recommendations. Patients are unlikely to accept removal of their allergy label on the basis of history alone. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: AN17/92982.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Savic L, Gurr L, Kaura V, et al. Penicillin allergy de-labelling ahead of elective surgery: feasibility and barriers. Br J Anaesth. 2018. PMID: 30915983. doi:10.1016/j.bja.2018.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。